Wigard P. Kloosterman PhD

Wigard Kloosterman holds a Ph.D. in Molecular Biology (2007) from Utrecht University. Until 2019, he was an Associate Professor at the Department of Genetics at the University Medical Center Utrecht, leading a research group in cancer genomics, with a particular focus on understanding complex genomic variants and their contribution to cancer phenotypes, such as drug response. He contributed to bringing knowledge from cancer genomics research to the clinic.

Furthermore, Dr. Kloosterman is a leading expert in genome sequencing technology, including computational analysis, and he has contributed multiple seminal papers in this field. He is at the forefront of implementing third-generation nanopore sequencing technology in research and clinical settings. Besides his role within Cyclomics, Dr. Kloosterman is appointed as CSO of Frame Cancer Therapeutics, an immunotherapy start-up in Amsterdam, aiming for the development of personalized cancer vaccines.